SL Science Reports 2025 Financial Results and Strategic Shift
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2026
0mins
Source: Newsfilter
- Declining Financial Performance: SL Science reported a net revenue of $2.20 million for 2025, a 35% decrease year-over-year, primarily due to the company's shift from direct retail to wholesale distribution, which negatively impacted overall financial health.
- Surge in Operating Expenses: Total operating expenses rose by 47% to $4.61 million, with general and administrative expenses increasing by 123%, reflecting significant investments in expanding the management team, which has added financial pressure in the short term.
- Continued R&D Investment: The company allocated $2.07 million to research and development, supporting parallel asset validation for its CD-19 Armed-T and GDT cell therapy products, demonstrating a strong commitment to future product development.
- Successful Listing and Financing: SL Science successfully listed on Nasdaq in June 2026 and completed a $7.8 million PIPE financing, providing essential funding to accelerate its growth strategy and support ongoing clinical research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLBT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLBT
Wall Street analysts forecast SLBT stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 4.450
Low
Averages
High
Current: 4.450
Low
Averages
High
No data
About SLBT
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
SL Science Reports 2025 Financial Results and Strategic Shift
- Declining Financial Performance: SL Science reported a net revenue of $2.20 million for 2025, a 35% decrease year-over-year, primarily due to the company's shift from direct retail to wholesale distribution, which negatively impacted overall financial health.
- Surge in Operating Expenses: Total operating expenses rose by 47% to $4.61 million, with general and administrative expenses increasing by 123%, reflecting significant investments in expanding the management team, which has added financial pressure in the short term.
- Continued R&D Investment: The company allocated $2.07 million to research and development, supporting parallel asset validation for its CD-19 Armed-T and GDT cell therapy products, demonstrating a strong commitment to future product development.
- Successful Listing and Financing: SL Science successfully listed on Nasdaq in June 2026 and completed a $7.8 million PIPE financing, providing essential funding to accelerate its growth strategy and support ongoing clinical research.
See More
Biotech Companies Achieve Significant Milestones
- NeOnc Breakthrough: NeOnc Technologies received IND authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant international regulatory milestone that is expected to accelerate global development efforts and boost investor confidence in the company's brain cancer treatment.
- SL Science Listing Success: SL Science completed its business combination with Horizon Space Acquisition II Corp., successfully listing on Nasdaq with an implied valuation of approximately $5.568 billion, enhancing its access to U.S. capital markets and attracting increased investor interest.
- CervoMed Strategic Update: CervoMed showcased its neurodegenerative disease programs at the H.C. Wainwright summit, particularly highlighting progress in aligning with the FDA on a registration pathway for neflamapimod, which could propel the company toward Phase 3 trials and maintain investor attention.
- Edgewise Cardiac Drug Progress: Edgewise Therapeutics reported positive results from its 12-week CIRRUS-HCM study, demonstrating the efficacy of EDG-7500 in hypertrophic cardiomyopathy patients, with plans to initiate Phase 3 trials in Q4 2026, potentially positioning the company as a new player in cardiovascular therapeutics.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: SL Science Holding Ltd. (SLBT) surged 200% to $10.00 in pre-market trading, indicating strong market demand and investor confidence, which may attract further capital inflows.
- Active Small-Cap Performers: CervoMed Inc. (CRVO) rose 25% to $3.09, while CAMP4 Therapeutics Corp. (CAMP) increased by 10% to $4.37, reflecting optimistic investor sentiment regarding growth potential in the biotech sector.
- Pre-Market Decliners: Cuprina Holdings (CUPR) fell 30% to $5.89, signaling market concerns about its future prospects, which could lead investors to reassess their investment strategies.
- Increased Market Volatility: The commencement of trading on Nasdaq, along with management news and proposed offerings, has heightened overall market sentiment volatility, prompting investors to approach potential market risks with caution.
See More
NASDAQ 100 Pre-Market Update
- Market Performance: The NASDAQ 100 Pre-Market Indicator is down 51.76 points to 30,492.16, indicating cautious market sentiment that may influence short-term investor decisions.
- Active Stocks: Space Exploration Technologies Corp. (SPCX) is up 8.61 points to $201.11 with a trading volume of 23,830,823 shares, marking a 52-week high that suggests optimistic market expectations for future growth.
- Target Price Analysis: Rackspace Technology, Inc. (RXT) is currently trading at $7.51, which is 150.17% above its target price of $5, indicating a reassessment of its value by the market that could attract more investor attention.
- ETF Performance: Vanguard Total International Stock ETF (VXUS) is up 0.52 points to $87.50, representing a 32.07% increase from its 52-week low, reflecting a recovery trend in international markets that may draw in funds seeking diversification.
See More
SL Bio Commences Trading on Nasdaq as SLBT
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, resulting in an implied valuation of approximately $5.568 billion, marking a significant strategic expansion in the biomedical sector.
- Funding for Innovative Therapies: The transaction includes a $7.8 million PIPE financing aimed at advancing SL Bio's proprietary Gamma delta T cell-based therapies, particularly for clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Executive Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-Nasdaq listing.
- Global Market Access: Listing on Nasdaq provides SL Bio direct access to U.S. institutional capital markets, enhancing financial flexibility to attract top-tier global scientific talent and facilitate future strategic acquisitions and global licensing partnerships.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
SL Science Reports 2025 Financial Results and Strategic Shift
- Declining Financial Performance: SL Science reported a net revenue of $2.20 million for 2025, a 35% decrease year-over-year, primarily due to the company's shift from direct retail to wholesale distribution, which negatively impacted overall financial health.
- Surge in Operating Expenses: Total operating expenses rose by 47% to $4.61 million, with general and administrative expenses increasing by 123%, reflecting significant investments in expanding the management team, which has added financial pressure in the short term.
- Continued R&D Investment: The company allocated $2.07 million to research and development, supporting parallel asset validation for its CD-19 Armed-T and GDT cell therapy products, demonstrating a strong commitment to future product development.
- Successful Listing and Financing: SL Science successfully listed on Nasdaq in June 2026 and completed a $7.8 million PIPE financing, providing essential funding to accelerate its growth strategy and support ongoing clinical research.
See More
Biotech Companies Achieve Significant Milestones
- NeOnc Breakthrough: NeOnc Technologies received IND authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant international regulatory milestone that is expected to accelerate global development efforts and boost investor confidence in the company's brain cancer treatment.
- SL Science Listing Success: SL Science completed its business combination with Horizon Space Acquisition II Corp., successfully listing on Nasdaq with an implied valuation of approximately $5.568 billion, enhancing its access to U.S. capital markets and attracting increased investor interest.
- CervoMed Strategic Update: CervoMed showcased its neurodegenerative disease programs at the H.C. Wainwright summit, particularly highlighting progress in aligning with the FDA on a registration pathway for neflamapimod, which could propel the company toward Phase 3 trials and maintain investor attention.
- Edgewise Cardiac Drug Progress: Edgewise Therapeutics reported positive results from its 12-week CIRRUS-HCM study, demonstrating the efficacy of EDG-7500 in hypertrophic cardiomyopathy patients, with plans to initiate Phase 3 trials in Q4 2026, potentially positioning the company as a new player in cardiovascular therapeutics.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: SL Science Holding Ltd. (SLBT) surged 200% to $10.00 in pre-market trading, indicating strong market demand and investor confidence, which may attract further capital inflows.
- Active Small-Cap Performers: CervoMed Inc. (CRVO) rose 25% to $3.09, while CAMP4 Therapeutics Corp. (CAMP) increased by 10% to $4.37, reflecting optimistic investor sentiment regarding growth potential in the biotech sector.
- Pre-Market Decliners: Cuprina Holdings (CUPR) fell 30% to $5.89, signaling market concerns about its future prospects, which could lead investors to reassess their investment strategies.
- Increased Market Volatility: The commencement of trading on Nasdaq, along with management news and proposed offerings, has heightened overall market sentiment volatility, prompting investors to approach potential market risks with caution.
See More
NASDAQ 100 Pre-Market Update
- Market Performance: The NASDAQ 100 Pre-Market Indicator is down 51.76 points to 30,492.16, indicating cautious market sentiment that may influence short-term investor decisions.
- Active Stocks: Space Exploration Technologies Corp. (SPCX) is up 8.61 points to $201.11 with a trading volume of 23,830,823 shares, marking a 52-week high that suggests optimistic market expectations for future growth.
- Target Price Analysis: Rackspace Technology, Inc. (RXT) is currently trading at $7.51, which is 150.17% above its target price of $5, indicating a reassessment of its value by the market that could attract more investor attention.
- ETF Performance: Vanguard Total International Stock ETF (VXUS) is up 0.52 points to $87.50, representing a 32.07% increase from its 52-week low, reflecting a recovery trend in international markets that may draw in funds seeking diversification.
See More
SL Bio Commences Trading on Nasdaq as SLBT
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, resulting in an implied valuation of approximately $5.568 billion, marking a significant strategic expansion in the biomedical sector.
- Funding for Innovative Therapies: The transaction includes a $7.8 million PIPE financing aimed at advancing SL Bio's proprietary Gamma delta T cell-based therapies, particularly for clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Executive Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-Nasdaq listing.
- Global Market Access: Listing on Nasdaq provides SL Bio direct access to U.S. institutional capital markets, enhancing financial flexibility to attract top-tier global scientific talent and facilitate future strategic acquisitions and global licensing partnerships.
See More
